21 - 30 of 422 Results
Condition Status ˆ Requirements ˇ Location Near You ˇ
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

201585-Study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current antiretroviral regimen in virologically suppressed HIV-1-infected adults
201585-Study evaluating the efficacy, safety, and tolerability of switching to long-acting cabotegravir plus long-acting rilpivirine from current antiretroviral regimen in virologically suppressed HIV-1-infected adults
Human Immunodeficiency Virus (HIV)
Recruiting
18+

To find a center near you, please provide a Country or Postal Code.

208090-Regimen switch to dolutegravir/lamivudine fixed dose combination from current antiretroviral regimen in HIV-1 infected and Virologically Suppressed Adults (SALSA)
208090-Regimen switch to dolutegravir/lamivudine fixed dose combination from current antiretroviral regimen in HIV-1 infected and Virologically Suppressed Adults (SALSA)
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

209493-Study to identify and determine best implementation practices for injectable cabotegravir+rilpivirine in the United States (US)
209493-Study to identify and determine best implementation practices for injectable cabotegravir+rilpivirine in the United States (US)
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

207966-Efficacy, safety and tolerability study of long-acting Cabotegravir Plus long-acting Rilpivirine (CAB LA + RPV LA) in human-immunodeficiency virus-1 (HIV-1) infected adults
207966-Efficacy, safety and tolerability study of long-acting Cabotegravir Plus long-acting Rilpivirine (CAB LA + RPV LA) in human-immunodeficiency virus-1 (HIV-1) infected adults
Human Immunodeficiency Virus (HIV)
Recruiting
18-50

To find a center near you, please provide a Country or Postal Code.

207863-Evaluation of the safety, tolerability and pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study
207863-Evaluation of the safety, tolerability and pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study
Human Immunodeficiency Virus (HIV)
Available
18+

To find a center near you, please provide a Country or Postal Code.

205741-GSK1265744 (Cabotegravir, CAB) for named patient/compassionate use in HIV
205741-GSK1265744 (Cabotegravir, CAB) for named patient/compassionate use in HIV
Human Immunodeficiency Virus (HIV)
Active, not recruiting
13+

To find a center near you, please provide a Country or Postal Code.

212333-One-arm meta-analysis of effectiveness of dolutegravir (DTG) based 2-drug regimen (2DR) in clinical practice
212333-One-arm meta-analysis of effectiveness of dolutegravir (DTG) based 2-drug regimen (2DR) in clinical practice
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

212355-Rapid test and treat dolutegravir plus lamivudine study in newly diagnosed Human immunodeficiency virus (HIV)-1 infected adults
212355-Rapid test and treat dolutegravir plus lamivudine study in newly diagnosed Human immunodeficiency virus (HIV)-1 infected adults
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

209672-Comparative effectiveness of fostemsavir
209672-Comparative effectiveness of fostemsavir
Human Immunodeficiency Virus (HIV)
Active, not recruiting
18+

To find a center near you, please provide a Country or Postal Code.

117175-Open-label study of dolutegravir (DTG) or efavirenz (EFV) for Human immunodeficiency virus (HIV) - Tuberculosis (TB) co-infection
117175-Open-label study of dolutegravir (DTG) or efavirenz (EFV) for Human immunodeficiency virus (HIV) - Tuberculosis (TB) co-infection